Pfizer Silences Testimony On Short-Term Prempro Use

Law360, New York (January 21, 2011, 7:38 PM EST) -- Plaintiffs in multidistrict litigation over Pfizer Inc.'s hormone replacement drug Prempro cannot present expert testimony that short-term use of the drug increases breast cancer risk, a judge has ruled on the eve of trial.

Dealing a blow to possibly hundreds of plaintiffs in the MDL, Judge William Wilson of the U.S. District Court for the Western District of Arkansas on Friday refused to reconsider a Wednesday order barring the testimony of the plaintiffs' expert epidemiologist, Dr. Donald Austin, from two cases set for trial Feb. 1....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.